Drugs / Olfactory mucosa-derived mesenchymal stem cells
Olfactory mucosa-derived mesenchymal stem cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05167552 | Mar 2022 → Dec 2023 | allergic rhinitis, chronic rhinosinusitis | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Unknown | No outcome recorded |
| Phase 1/2 | NCT03130374 | Jan 2017 → Jan 2019 | laryngostenosis, tracheal stenosis | The Republican Research and Practical Center for Epidemiology and Microbiology | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05535803 | Jun 2021 → Jun 2023 | laryngostenosis, tracheal stenosis | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olfactory mucosa-derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03130374 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells based therapy” NCT03130374 ↗ |
| Route | Other | “is injected submucosally around and over the tissue” NCT03130374 ↗ |